PRS-344 is under clinical development by Pieris Pharmaceuticals and currently in Phase II for Solid Tumor. According to GlobalData, Phase II drugs for Solid Tumor have a 10% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how PRS-344’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
PRS-344 is under development for the treatment of solid tumors including extensive stage small cell lung cancer or locally advanced or metastatic squamous cell carcinoma of the esophagus. It is a bispecific antibody-Anticalin fusion protein comprising an PD-L1-targeting antibody genetically fused to Anticalin proteins specific for 4-1BB. The therapeutic candidate acts by targeting programmed cell death 1 ligand 1 and tumor necrosis factor receptor superfamily member 9. It is developed based on Anticalin technology. It is administered through intravenous route.
Pieris Pharmaceuticals overview
Pieris Pharmaceuticals (Pieris) is a clinical-stage biotechnology company that carries out the discovery and development of anticalin-based drugs. The company’s pipeline product includes inhaled IL-4Ra antagonist Anticalin protein. It offers drug candidates such as PRS-060/AZD1402, PRS-220, PRS-440, PRS-342 and PRS-352, among others. Pieris also carries out AstraZenca programs and Genetech programs against respiratory diseases. The company offers therapeutics for the treatment of respiratory diseases, oncology and other diseases. It leverages Anticalin technology platform to develop and advance its pipeline candidates. Pieris collaborates with AstraZeneca Plc, Boston Pharmaceuticals, Servier SAS, Genentech and Seattle Genetics Inc to develop drug candidates. It operates in the US, Australia and Germany. Pieris is headquartered in Boston, Massachusetts, the US.
For a complete picture of PRS-344’s drug-specific PTSR and LoA scores, buy the report here.